ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2023 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced…